completed

The objective of the REMIT-iGarLixi study is to determine if, in patients with recently diagnosed T2DM, a 12-week course of iGlarLixi (combined basal insulin glargine and lixisenatide), metformin, and lifestyle approaches will achieve drug-free diabetes remission in a higher proportion of patients than standard diabetes therapy at 24 weeks (three months after the drugs are stopped).

Participants will be randomized to two treatment groups:

  • A 12-week course of treatment with iGLarLixi, metformin, and lifestyle therapy, and;
  • Standard diabetes therapy, and followed for a total of 64 weeks.

The primary outcome in this trial will be diabetes remission evaluated at 24 weeks after randomization.

Study Type

Interventional - Drug

Study Design

A multicentre, open-label, randomized controlled trial

NO. of Countries

1

NO. of Sites

8

NO. of Participants

161

Study Period

2017-2020

Sponsor

PHRI

Sanofi

Back To Top